# Celyad Oncology SA (CYAD)

Source: https://www.quantisnow.com/company/CYAD
Generated: 2026-11-16T02:58:30.277Z

- Ticker: CYAD
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2015
- Website: celyad.com

## About

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T therapy that is in Phase 1 clinical trial for the treatment of hematological malignancies and solid tumors. The company's preclinical candidates, include allogeneic CAR-T candidate for the treatment of solid tumors; CYAD-221, shRNA based allogeneic CAR-T candidate to treat B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting natural killer group 2D ligands (NKG2D) and an undisclosed membrane protein. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

## Latest CYAD news and filings

- 2026-09-23 20:05 UTC [Earnings] [Celyad Oncology Reports First Half Year 2026 Results](https://www.quantisnow.com/insight/celyad-oncology-reports-first-half-year-2026-results-6724126)
- 2026-07-28 20:00 UTC [Publication of a Transparency Notification Received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)](https://www.quantisnow.com/insight/publication-of-a-transparency-notification-received-from-tolefi-sa-article-6651273)
- 2026-07-22 18:45 UTC [Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)](https://www.quantisnow.com/insight/celyad-oncology-information-on-the-total-number-of-voting-rights-6645035)
- 2026-07-14 07:32 UTC [Celyad Oncology Announces €500,000 Private Placement](https://www.quantisnow.com/insight/celyad-oncology-announces-500000-private-placement-6635846)
- 2024-02-09 11:07 UTC [SEC Form 15F-12B filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-15f-12b-filed-by-celyad-oncology-sa-5243351)
- 2024-01-17 11:33 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-5189882)
- 2023-12-21 11:19 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-5149931)
- 2023-12-18 17:29 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-5143062)
- 2023-12-04 18:28 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-5116159)
- 2023-12-04 18:26 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-5116157)
- 2023-11-24 13:54 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-5102375)
- 2023-11-21 21:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-5098712)
- 2023-11-21 13:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-5097675)
- 2023-11-15 21:37 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-5088024)
- 2023-09-26 10:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-4987162)
- 2023-09-22 10:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-4983538)
- 2023-09-18 10:04 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-4974325)
- 2023-09-13 10:29 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-4967738)
- 2023-09-11 10:21 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-4962778)
- 2023-09-06 10:04 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-4954429)
- 2023-09-05 20:32 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Celyad Oncology SA (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-celyad-oncology-sa-amendment-4953480)
- 2023-09-05 10:12 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-4951254)
- 2023-08-25 10:07 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-4937767)
- 2023-08-24 20:26 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Celyad Oncology SA (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-celyad-oncology-sa-amendment-4937106)
- 2023-07-10 10:04 UTC [SEC Form 25-NSE filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-celyad-oncology-sa-4733534)
- 2023-05-15 23:21 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-4509921)
- 2023-05-15 20:30 UTC [Market Insight] [Celyad Oncology Announces Receipt Of Nasdaq Delisting Notice](https://www.quantisnow.com/insight/celyad-oncology-announces-receipt-of-nasdaq-delisting-notice-4507159)
- 2023-05-15 20:01 UTC [Celyad Oncology announces receipt of Nasdaq delisting notice](https://www.quantisnow.com/insight/celyad-oncology-announces-receipt-of-nasdaq-delisting-notice-4505452)
- 2023-05-05 13:06 UTC [Market Insight] [12 Health Care Stocks Moving In Friday's Pre-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-fridays-pre-market-session-4452620)
- 2023-05-05 11:22 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-4451792)
- 2023-05-05 11:21 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-4451787)
- 2023-05-05 08:05 UTC [Market Chatter] [Celyad Oncology Has Approved Voluntary Delisting Of American Depositary Shares From NASDAQ, The Company Will Continue To Be Listed On Euronext Brussels](https://www.quantisnow.com/insight/celyad-oncology-has-approved-voluntary-delisting-of-american-depositary-shares-4450845)
- 2023-05-05 08:03 UTC [Market Chatter] [Celyad Oncology As of March 31, 2023, Had Cash And Cash Equivalents of €9.2M Sufficient To Provide Cash Runway Into Q4 2023](https://www.quantisnow.com/insight/celyad-oncology-as-of-march-31-2023-had-cash-and-4450844)
- 2023-05-05 05:00 UTC [Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq](https://www.quantisnow.com/insight/celyad-oncology-announces-intent-to-voluntarily-delist-american-depository-shares-4450789)
- 2023-05-05 05:00 UTC [Celyad Oncology reports first quarter 2023 financial results and recent business highlights](https://www.quantisnow.com/insight/celyad-oncology-reports-first-quarter-2023-financial-results-and-recent-4450788)
- 2023-04-24 20:13 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-4374740)
- 2023-04-24 20:01 UTC [Celyad Oncology announces receipt of Nasdaq initial notification on ADS bid price](https://www.quantisnow.com/insight/celyad-oncology-announces-receipt-of-nasdaq-initial-notification-on-ads-4374395)
- 2023-04-19 17:30 UTC [Market Insight] [12 Health Care Stocks Moving In Wednesday's Intraday Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-wednesdays-intraday-session-4356016)
- 2023-04-05 11:45 UTC [SEC Form 6-K] [SEC Form 6-K filed by Celyad Oncology SA](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-celyad-oncology-sa-4300778)
- 2023-04-05 04:32 UTC [Market Insight] [Reported Late Tuesday April 4, Celyad Oncology Announces Receipt Of Nasdaq Notice Informing The Company That It Failed To Maintain The Continued Listing Requirement Under Nasdaq Listing Rule 5450(b)(1)(A)](https://www.quantisnow.com/insight/reported-late-tuesday-april-4-celyad-oncology-announces-receipt-of-4300000)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/CYAD
- Earnings history: https://www.quantisnow.com/earnings/CYAD
- Dividend history: https://www.quantisnow.com/dividends/CYAD
- Insider transactions: https://www.quantisnow.com/insiders/CYAD
- Options chain: https://www.quantisnow.com/options/CYAD
- SEC 8-K filings only: https://www.quantisnow.com/company/CYAD/8-k
- RSS and alerts for CYAD: https://www.quantisnow.com/docs/rss-feeds.md
